Session Information
ASHP Summer Meeting 2006
Click here to go to the previous page
Anticoagulant-Related Bleeding; Genetic Variations; Emerging Anticoagulant Agents
Track:
Sessions
Program Code: 132-L01
Date: Tuesday, June 27, 2006
Time: 8:00 AM to 10:00 AM
SPEAKER(S):
Click the plus sign to see more detailed information about each speaker.
Click the plus sign to see more detailed information about each speaker.
Stuart Haines, PharmD, BCPS, Professor and Vice Chair for Education, University of Maryland School of Pharmacy Dr. Edith Nutescu, PharmD, FCCP, Clinical Associate Professor and Director, Antithrombosis Center, University of Illinois at Chicago, College of Pharmacy
Ann K. Wittkowsky, Pharm.D., CACP, FASHP, Director, Anticoagulation Services, University of Washington Medical Center
Description
Learning Objectives:
Identify patient characteristics that increase the risk for anticoagulant-related bleeding.
Recommend an appropriate management plan for a patient who experiences an anticoagulant-related bleed including the use of reversal agents.
Evaluate the role of genetics in warfarin metabolism and vitamin K hepatic recycling.
Explain the impact of heredity on patient response to oral anticoagulation therapy.
Review the pharmacology of new and emerging anticoagulant agents.
Discuss available clinical data and potential future role in therapy of novel anticoagulant agents.
Explain the possible impact on anticoagulation clinical practice of emerging anticoagulant agents.
Identify patient characteristics that increase the risk for anticoagulant-related bleeding.
Recommend an appropriate management plan for a patient who experiences an anticoagulant-related bleed including the use of reversal agents.
Evaluate the role of genetics in warfarin metabolism and vitamin K hepatic recycling.
Explain the impact of heredity on patient response to oral anticoagulation therapy.
Review the pharmacology of new and emerging anticoagulant agents.
Discuss available clinical data and potential future role in therapy of novel anticoagulant agents.
Explain the possible impact on anticoagulation clinical practice of emerging anticoagulant agents.
| No items are available for this session. |